The Middle East liquid biopsy market size was valued at USD 104.76 million in 2024 and is projected to reach USD 233.95 billion by 2033, growing at a CAGR of 9.28% from 2025 to 2033. The market is driven by increased emphasis on early detection and population-level screening initiatives across the Middle East, fueled by rising cancer prevalence.
For example, in December 2024, Abu Dhabi launched a new blood-based colon cancer test as part of a proactive strategy to improve early detection and survival rates. The program addresses a significant gap in early diagnosis.
In addition, according to data from 2023, 67% of cases of colorectal cancer in Abu Dhabi were discovered at a late stage, which limited treatment options and decreased survival rates. The program, which offers a non-invasive alternative to traditional screening methods, is expected to enhance patient participation and support the UAE broader efforts to improve early detection and outcomes. The market for non-invasive early detection technologies is growing beyond advanced-stage cancer, and the Middle East liquid biopsy market is being boosted by new blood-based screening programs for colorectal and lung cancer.
Rising government and health-system adoption, supported by national pilot programs, is fueling market growth by encouraging wider testing and strengthening healthcare readiness. For instance, in June 2025, M42 entered into a strategic partnership with AstraZeneca and SOPHiA GENETICS to bring advanced liquid biopsy testing to the UAE, supporting cancer diagnosis, guiding treatment choices, and enabling quicker and more accurate biomarker analysis across various cancer types. Through this collaboration, M42 adopted SOPHiA GENETICS’ MSK-ACCESS, powered by the SOPHiA DDM platform, within its testing network, allowing for non-invasive genomic profiling using a simple blood sample.
Government-supported screening initiatives and hospital-led validation studies, such as evaluation by Cleveland Clinic Abu Dhabi and the Abu Dhabi colorectal cancer program, are accelerating early clinical adoption, increasing in test reliability, and moving reimbursement awareness forward throughout the region. The new testing initiative will initially focus on lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the region's most pressing cancer issues. Over the next year, the partnership will expand access to liquid biopsy testing to selected major hospitals in the UAE, providing patients with faster and less invasive biomarker insights than traditional tissue biopsies, while also increasing the country's testing capacity and cancer diagnostic capabilities.
Moreover, regional pharmaceutical and medical groups are entering exclusive distribution and partnership agreements that expand commercial availability and strengthen regional laboratory services. For instance, in June 2022, Imagia Canexia Health (Canada) signed a Memorandum of Understanding (MOU) with the Kingdom of Saudi Arabia to distribute its liquid biopsy testing products throughout Saudi Arabia and Middle East region. The company offers liquid biopsy solutions for therapy selection and patient monitoring that can be performed at or near the point of care, eliminating the need to send samples to international centralized laboratories. This approach allows cancer patients all across the region to access advanced precision oncology treatments at a lower cost and faster turnaround time. Such collaborations remove key access barriers, standardize test delivery across local markets, and accelerate the liquid biopsy market's growth.
Furthermore, growing strategic partnerships and commercial rollouts are fueling the Middle East liquid biopsy market, enabling global companies to work closely with regional clinical stakeholders. For instance, in January 2024, Hikma Pharmaceuticals PLC (UK) entered into an agreement with Guardant Health, Inc. (US) for commercialization and marketing of Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in the Middle East. In addition, the portfolio features tests such as Shield for early cancer screening, Guardant Reveal for detecting minimal residual disease and tracking recurrence, and Guardant360 along with Guardant360 TissueNext for comprehensive genomic profiling (CGP) across all solid tumors. These alliances help to launch and expand liquid biopsy products across the Middle East, improving accessibility, streamlining distribution, and significantly accelerating market entry and scale-up.
This product will be delivered within 2 business days.
For example, in December 2024, Abu Dhabi launched a new blood-based colon cancer test as part of a proactive strategy to improve early detection and survival rates. The program addresses a significant gap in early diagnosis.
In addition, according to data from 2023, 67% of cases of colorectal cancer in Abu Dhabi were discovered at a late stage, which limited treatment options and decreased survival rates. The program, which offers a non-invasive alternative to traditional screening methods, is expected to enhance patient participation and support the UAE broader efforts to improve early detection and outcomes. The market for non-invasive early detection technologies is growing beyond advanced-stage cancer, and the Middle East liquid biopsy market is being boosted by new blood-based screening programs for colorectal and lung cancer.
Rising government and health-system adoption, supported by national pilot programs, is fueling market growth by encouraging wider testing and strengthening healthcare readiness. For instance, in June 2025, M42 entered into a strategic partnership with AstraZeneca and SOPHiA GENETICS to bring advanced liquid biopsy testing to the UAE, supporting cancer diagnosis, guiding treatment choices, and enabling quicker and more accurate biomarker analysis across various cancer types. Through this collaboration, M42 adopted SOPHiA GENETICS’ MSK-ACCESS, powered by the SOPHiA DDM platform, within its testing network, allowing for non-invasive genomic profiling using a simple blood sample.
Government-supported screening initiatives and hospital-led validation studies, such as evaluation by Cleveland Clinic Abu Dhabi and the Abu Dhabi colorectal cancer program, are accelerating early clinical adoption, increasing in test reliability, and moving reimbursement awareness forward throughout the region. The new testing initiative will initially focus on lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the region's most pressing cancer issues. Over the next year, the partnership will expand access to liquid biopsy testing to selected major hospitals in the UAE, providing patients with faster and less invasive biomarker insights than traditional tissue biopsies, while also increasing the country's testing capacity and cancer diagnostic capabilities.
Moreover, regional pharmaceutical and medical groups are entering exclusive distribution and partnership agreements that expand commercial availability and strengthen regional laboratory services. For instance, in June 2022, Imagia Canexia Health (Canada) signed a Memorandum of Understanding (MOU) with the Kingdom of Saudi Arabia to distribute its liquid biopsy testing products throughout Saudi Arabia and Middle East region. The company offers liquid biopsy solutions for therapy selection and patient monitoring that can be performed at or near the point of care, eliminating the need to send samples to international centralized laboratories. This approach allows cancer patients all across the region to access advanced precision oncology treatments at a lower cost and faster turnaround time. Such collaborations remove key access barriers, standardize test delivery across local markets, and accelerate the liquid biopsy market's growth.
Furthermore, growing strategic partnerships and commercial rollouts are fueling the Middle East liquid biopsy market, enabling global companies to work closely with regional clinical stakeholders. For instance, in January 2024, Hikma Pharmaceuticals PLC (UK) entered into an agreement with Guardant Health, Inc. (US) for commercialization and marketing of Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in the Middle East. In addition, the portfolio features tests such as Shield for early cancer screening, Guardant Reveal for detecting minimal residual disease and tracking recurrence, and Guardant360 along with Guardant360 TissueNext for comprehensive genomic profiling (CGP) across all solid tumors. These alliances help to launch and expand liquid biopsy products across the Middle East, improving accessibility, streamlining distribution, and significantly accelerating market entry and scale-up.
Middle East Liquid Biopsy Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, the analyst has segmented the liquid biopsy market on the basis product, sample type, technology, biomarker, application, clinical application, end use, and country.Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments
- Consumables Kits and Reagents
- Software and Services
Sample Type Outlook (Revenue, USD Million, 2021-2033)
- Blood Sample
- Others
Technology Outlook (Revenue, USD Million, 2021-2033)
- Multi-gene parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
Biomarker Outlook (Revenue, USD Million, 2021-2033)
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins
Application Outlook (Revenue, USD Million, 2021-2033)
- Cancer
- Reproductive Health
- Others
Clinical Application Outlook (Revenue, USD Million, 2021-2033)
- Therapy Selection
- Treatment Monitoring
- Early Cancer Screening
- Recurrence Monitoring
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others
Country Outlook (Revenue, USD Million, 2021-2033)
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
- Rest of Middle East
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East Liquid Biopsy Market Variables, Trends & Scope
Chapter 4. Middle East Liquid Biopsy Market: Product Estimates & Trend Analysis
Chapter 5. Middle East Liquid Biopsy Market: Sample Type Estimates & Trend Analysis
Chapter 6. Middle East Liquid Biopsy Market: Technology Estimates & Trend Analysis
Chapter 7. Middle East Liquid Biopsy Market: Biomarker Estimates & Trend Analysis
Chapter 8. Middle East Liquid Biopsy Market: Application Estimates & Trend Analysis
Chapter 9. Middle East Liquid Biopsy Market: Clinical Application Estimates & Trend Analysis
Chapter 10. Middle East Liquid Biopsy Market: End-use Estimates & Trend Analysis
Chapter 11. Middle East Liquid Biopsy Market: Regional Estimates & Trend Analysis
Chapter 12. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this Middle East Liquid Biopsy market report include:- CelLBxHealth
- Oncimmune Holdings PLC
- Guardant Health, Inc.
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche Ltd
- QIAGEN
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- Epigenomics AG
- NeoGenomics Laboratories.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 104.76 Million |
| Forecasted Market Value ( USD | $ 233.95 Million |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
